Obermatt

Daiichi Sankyo

TYO:4568 · JP3475350009
PharmaceuticalsX-Large

360

56
EV / EBIT62
Price / Owner Earnings54
Owner Earnings Yield64
Dividend Yield93
Price/Sales40
EV / Gross Profit85
Price/Book25
Return on Capital45
Cash Return on Capital57
Return on Equity65
EBIT Margin12
Gross Profitability54
Cash Conversion1
Accruals14
Owner Earnings Margin27
Sales growth63
Profit Growth15
Long-Term EPS Growth56
Owner Earnings Growth20
Reinvestment70
Price momentum24
Debt load67
Refinancing37
Debt Payback100
Liquidity84
Analyst ratings74
Opinion Changes50
Price Target Upside98
Market mood100
Value Creation14/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Daiichi Sankyo generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryJapan
IndustryPharmaceuticals
SizeX-Large
TypePublic Company
ExchangeTSE
Founded2005
Employees1,105
ISINJP3475350009
Last UpdateApr 2, 2026
Themes
OsteoporosisPain ManagementInfectious DiseasesHematologyImmunologyVaccinesDiabetesCardiovascularOncologyBiotechnologyHealth CarePharmaceutical

Description

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products. Business Segments The company operates through several business segments, each contributing to the company’s overall growth and value creation. The company’s primary bu…

Analysis

Deep value

Daiichi Sankyo Company, Limited lands in the deep-value zone: the price is very low, but so are the business fundamentals. One caution: reported profits have recently run ahead of actual cash, which we track closely.

The price is fair. You pay 20.4× its owner earnings: the cash an owner could take out each year, which is in the historically fair zone. At today's price, the market is assuming roughly 6% yearly growth; analysts expect 11%. The price, in other words, assumes less than the experts do.

The trajectory is tepid and the balance sheet is sturdy. The company scores 14/20 on our value-creation score: strong value creator.

What to watch: Some accounting patterns deserve a closer look. Some accounting patterns deserve a closer look. Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
79
2023202420252026

All-time high

89

Mar 2026

All-time low

33

Jun 2023

Average rank

72

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
40
31
24
28
Price/Earnings
40
37
17
12
Price/Book
25
23
18
28
Dividend Yield
93
55
41
28
Value (overall)
41
26
16
15

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Daiichi Sankyo with its peers
Pyridam Farma
JKT:PYFA
3
CountrySingapore
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Sawai Pharmaceutical
TYO:4887
44
CountryJapan
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Tsumura
TYO:4540
47
CountryJapan
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Kyongbo Pharmaceutical
KSC:214390
11
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Ono Pharmaceutical
TYO:4528
87
CountryJapan
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Handok
KSC:002390
15
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →